|
1
|
Jemal A, Murray T, Ward E, et al: Cancer
statistics, 2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Center MM, Jemal A, Smith RA and Ward E:
Worldwide variations in colorectal cancer. CA Cancer J Clin.
59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bary F, Center MM, et al: Global
cancer statistic. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saif MW: Targeted agents for adjuvant
therapy of colon cancer. Clin Colorectal Canc. 6:46–51. 2006.
View Article : Google Scholar
|
|
5
|
Macdonald JS: Adjuvant therapy of colon
cancer. CA Cancer J Clin. 49:202–219. 1999. View Article : Google Scholar
|
|
6
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Delval L and Klastersky J: Optic
neuropathy in cancer patients. Report of a case possibly related to
5 fluorouracil toxicity and review of the literature. J Neurooncol.
60:165–169. 2002. View Article : Google Scholar
|
|
8
|
Meregalli M, Martignoni G, Frontini L, et
al: Increasing doses of 5-fluorouracil and high-dose folinic acid
in the treatment of metastatic colorectal cancer. Tumori.
84:662–665. 1998.
|
|
9
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ziegler DS and Kung AL: Therapeutic
targeting of apoptosis pathways in cancer. Curr Opin Oncol.
20:97–103. 2008. View Article : Google Scholar
|
|
11
|
Wong RSY: Apoptosis in cancer: from
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Green DR and Kroemer G: The
pathophysiology of mitochondrial cell death. Science. 305:626–629.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Borner C: The Bcl-2 protein family:
sensors and checkpoints for life-or-death decisions. Mol Immunol.
39:615–647. 2003. View Article : Google Scholar
|
|
14
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Willis SN, Fletcher J, Kaufmann T, et al:
Apoptosis initiated when BH3 ligands engage multiple Bcl-2
homologs, not Bax or Bak. Science. 315:856–859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tin MM, Cho CH, Chan K, et al: Astragalus
saponins induce growth inhibition and apoptosis in human colon
cancer cells and tumor xenograft. Carcinogenesis. 28:1347–1355.
2007. View Article : Google Scholar
|
|
17
|
Miller K, Wang ML, Gralow J, et al:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. New Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Phillips PA, Sangwan V, Borja-Cacho D, et
al: Myricetin induces pancreatic cancer cell death via the
induction of apoptosis and inhibition of the phosphatidylinositol
3-kinase (PI3K) signaling pathway. Cancer Lett. 308:181–188. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morimoto S, Nonaka GI and Nishioka I:
Tannins and related compounds. LX. Isolation and characterization
of proanthocy-anidins with a doubly-linked unit from Vaccinium
vitis-idaea L. Chem Pharm Bull. 36:33–38. 1988. View Article : Google Scholar
|
|
20
|
Fokina GI, Roĭkhel’ VM, Frolova MP, et al:
The antiviral action of medicinal plant extracts in experimental
tick-borne encephalitis. Vopr Virusol. 38:170–173. 1993.In Russian.
PubMed/NCBI
|
|
21
|
Tong QY, Qing Y, Shu D, et al: Deltonin, a
steroidal saponin, inhibits colon cancer cell growth in vitro and
tumor growth in vivo via induction of apoptosis and
antiangiogenesis. Cell Physiol Biochem. 27:233–242. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jeone SJ, Koh W, Kim B and Kim SH: Are
there new therapeutic options for treating lung cancer based on
herbal medicines and their metabolites. J Ethnopharmacology.
138:652–661. 2011. View Article : Google Scholar
|
|
23
|
Wang J, Zhao XZ, Qi Q, et al:
Macranthoside B, a hederagenin saponin extracted from Lonicera
macranthoides and its anti-tumor activities in vitro and in vivo.
Food Chem Toxicol. 47:1716–1721. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu M, Xu L, Yin LH, et al: Cytotoxicity of
dioscin in human gastric carcinoma cells through death receptor and
mitochondrial pathways. J Appl Toxicol. 33:712–722. 2013.
View Article : Google Scholar
|
|
25
|
Cai SX, Drewe J and Kasibhatla S: A
chemical genetics approach for the discovery of apoptosis inducers:
from phenotypic cell based HTS assay and structure-activity
relationship studies, to identification of potential anticancer
agents and molecular targets. Curr Med Chem. 13:2627–2644. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hickman JA: Apoptosis induced by
anticancer drugs. Cancer Metastasis Rev. 11:121–139. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Desagher S and Martinous JC: Mitochondria
as the central control point of apoptosis. Trends Cell Biol.
10:369–377. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gabriel B, Sureau F, Casselyn M, et al:
Retroactive pathway involving mitochondria in electroloaded
cytochrome c-induced apoptosis. Protective properties of Bcl-2 and
Bcl-XL. Exp Cell Res. 289:195–210. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maianski NA, Roos D and Kuijpers TW: Bid
truncation, bid/bax targeting to the mitochondria, and caspase
activation associated with neutrophil apoptosis are inhibited by
granulocyte colony-stimulating factor. J Immunol. 172:7024–7030.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nuñez G, Benedict MA, Hu Y and Inohara N:
Caspases: the proteases of the apoptotic pathway. Oncogene.
17:3237–3245. 1998. View Article : Google Scholar
|
|
31
|
Duriez PJ and Shah G: Cleavage of
poly(ADP-ribose) polymerase: a sensitive parameter to study cell
death. Biochem Cell Biol. 75:337–349. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cory S and Adams JM: The Bcl2 family:
regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oltersdorf T, Elmore SW, Shoemaker AR, et
al: An inhibitor of Bcl-2 family proteins induces regression of
solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Murray A: Cyclin ubiquitination: the
destructive end of mitosis. Cell. 81:149–152. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Antonsson B and Martinou JC: The Bcl-2
protein family. Exp Cell Res. 256:50–57. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Reed JC: Double identity for protein of
the Bcl-2 family. Nature. 387:773–776. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mirjolet JF, Barberi-Heyob M, Didelot C,
et al: Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity
independently of p53 status. Br J Cancer. 83:1380–1386. 2000.
View Article : Google Scholar : PubMed/NCBI
|
